Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/109500
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Falcon Neyra, Lola | - |
dc.contributor.author | Palladino, Claudia | - |
dc.contributor.author | Navarro Gómez, María Luisa | - |
dc.contributor.author | Soler Palacín, Pere | - |
dc.contributor.author | González Tomé, Maria Isabel | - |
dc.contributor.author | Ory, Santiago J. de | - |
dc.contributor.author | Frick, Marie Antoniette | - |
dc.contributor.author | Fortuny Guasch, Claudia | - |
dc.contributor.author | Noguera Julian, Antoni | - |
dc.contributor.author | Bermúdez Moreno, Elena | - |
dc.contributor.author | Santos, Juan Luis | - |
dc.contributor.author | Olbrich, Peter | - |
dc.contributor.author | López Cortés, Luis F. | - |
dc.contributor.author | Briz, Verónica | - |
dc.contributor.author | Neth, Olaf | - |
dc.contributor.author | CoRISpe working group | - |
dc.date.accessioned | 2017-04-06T14:10:46Z | - |
dc.date.available | 2017-04-06T14:10:46Z | - |
dc.date.issued | 2016-06 | - |
dc.identifier.issn | 0025-7974 | - |
dc.identifier.uri | http://hdl.handle.net/2445/109500 | - |
dc.description.abstract | To assess the safety and efficacy of rilpivirine in combination with emtricitabine and tenofovir (RPV/FTC/TDF) as a once-daily single-tablet regimen (STR) in HIV-1-infected children and adolescents we performed a multicenter case series study of HIV-1-infected patients. Inclusion criteria were initiation of therapy with RPV/FTC/TDF before the age of 18. Patients were divided into undetectable viral load (uVL) group, HIV-1 RNA < 20 copies/mL on stable combined antiretroviral therapy (cART), and detectable viral load (dVL) group, HIV-1 RNA ≥ 20 copies/mL at RPV/FTC/TDF initiation. Patients were monitored from the date of RPV/FTC/TDF initiation until June 30, 2015, RPV/FTC/TDF discontinuation or failure to follow-up. Seventeen patients (8 in uVL and 9 in dVL group) with age between 11.6 and 17.6 were included. Reasons for switching were toxicity (n = 4) and simplification (n = 4) in uVL; viral failure (n = 8) and cART initiation (n = 1) in the dVL group. After a median follow-up of 90 (uVL) and 40 weeks (dVL), 7/8 (86%) patients maintained and 8/9 (89%) achieved and maintained HIV-1 suppression. Median CD4 count increased from 542 to 780/μL (uVL, P = 0.069) and 480 to 830/μL (dVL, P = 0.051). Five patients (2 in uVL and 3 in dVL) improved their immunological status from moderate to no immunosuppression. Serum lipid profiles improved in both groups; cholesterol dropped significantly in the dVL group (P = 0.008). Grade 1 laboratory adverse events (AEs) were observed in 3 patients. No clinical AEs occurred. Adherence was complete in 9 patients (5 in uVL and 4 in dVL); 1 adolescent interrupted treatment. Once-daily STR with RPV/FTC/TDF may be a safe and effective choice in selected HIV-1-infected adolescents and children. | - |
dc.format.extent | 5 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Lippincott, Williams & Wilkins. Wolters Kluwer Health | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1097/MD.0000000000003842 | - |
dc.relation.ispartof | Medicine, 2016, vol. 95, num. 24, p. e3842 | - |
dc.relation.uri | https://doi.org/10.1097/MD.0000000000003842 | - |
dc.rights | cc-by (c) Falcon Neyra, Lola et al., 2016 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques) | - |
dc.subject.classification | VIH (Virus) | - |
dc.subject.classification | Antiretrovirals | - |
dc.subject.classification | Inhibidors enzimàtics | - |
dc.subject.classification | Sida en els infants | - |
dc.subject.classification | Pediatria | - |
dc.subject.other | HIV (Viruses) | - |
dc.subject.other | Antiretroviral agents | - |
dc.subject.other | Enzyme inhibitors | - |
dc.subject.other | AIDS (Disease) in children | - |
dc.subject.other | Pediatrics | - |
dc.title | Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter study. | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 668933 | - |
dc.date.updated | 2017-04-06T14:10:46Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 27310962 | - |
Appears in Collections: | Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
668933.pdf | 183.94 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License